The kidney and cardiovascular risk – Implications for management: A consensus statement from the European Society of Hypertension

References

• Brosius F. C., Hostetter T. H., Kelepouris E., Mitsnefes M. M., Moe S. M., Moore M. A., et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: A science advisory from the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: Developed in Collaboration With the National Kidney Foundation. Circulation 2006; 114: 1083–1087
   PubMed Web of Science ®Google Scholar
• Dzau V., Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: A workshop consensus statement. Am Heart J 1991; 121: 1244–1263
   PubMed Web of Science ®Google Scholar
• Zanchetti A. Evidence‐based medicine in hypertension: What type of evidence?. J Hypertens 2005; 23: 1113–1120
   PubMed Web of Science ®Google Scholar
• Segura J., Garcia‐Donaire J. A., Praga M., Ruilope L. M. Chronic kidney disease as a situation of high added risk in hypertensive patients. J Am Soc Nephrol 2006; 17 Suppl 2: S136–S140
   Web of Science ®Google Scholar
• Ruilope L. M., van Veldhuisen D. J., Ritz E., Luscher T. F. Renal function: The Cinderella of cardiovascular risk profile. J Am Coll Cardiol 2001; 38: 1782–1787
   PubMed Web of Science ®Google Scholar
• Go A. S., Chertow G. M., Fan D., McCulloch C. E., Hsu C. Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296–1305
   PubMed Web of Science ®Google Scholar
• Chobanian A. V., Bakris G. L., Black H. L., Cushman W. C., Green L. A., Izzo J. L., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252
   PubMed Web of Science ®Google Scholar
• Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053
   PubMed Web of Science ®Google Scholar
• K‐DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1–S290
   Google Scholar
• Lewis E. J., Hunsicker L. G., Bain R. P., Rohde R. D. The effect of angiotensin‐converting‐enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456–1462
   PubMed Web of Science ®Google Scholar
• Brenner B. M., Cooper M. E., de Zeeuw D., Keane W. F., Mitch W. E., Parving H. H., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869
   PubMed Web of Science ®Google Scholar
• Wright J. T., Bakris G., Greene T., Agodoa L. Y., Appel L. J., Charleston J., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 2002; 288: 2421–2431
   PubMed Web of Science ®Google Scholar
• Segura J., Campo C., Rodicio J. L., Ruilope L. M. ACE inhibitors and appearance of renal events in hypertensive nephrosclerosis. Hypertension 2001; 38: 645–649
   PubMed Web of Science ®Google Scholar
• De Zeeuw D., Remuzzi G., Parving H. H., Keane W. F., Zhang Z., Shahinfar S., et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921–927
   PubMed Web of Science ®Google Scholar
• Bakris G. L. Implications of albuminuria on kidney disease progression. J Clin Hypertens (Greenwich) 2004; 6 Suppl 3: 18–22
   Google Scholar
• Ruggenenti P., Perna A., Loriga G., Ganeva M., Ene‐Iordache B., Turturro M., et al. Blood‐pressure control for renoprotection in patients with non‐diabetic chronic renal disease (REIN‐2): Multicentre, randomised controlled trial. Lancet 2005; 365: 939–946
   PubMed Web of Science ®Google Scholar
• Nakao N., Yoshimura A., Morita H., Takada M., Kayano T., Ideura T. Combination treatment of angiotensin‐II receptor blocker and angiotensin‐converting‐enzyme inhibitor in non‐diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 2003; 361: 117–124
   PubMed Web of Science ®Google Scholar
• Nakao N., Seno H., Kasuga H., Toriyama T., Kawahara H., Fukagawa M. Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non‐diabetic renal disease: A COOPERATE‐ABP substudy. Am J Nephrol 2004; 24: 543–548
   PubMed Web of Science ®Google Scholar
• MacKinnon M., Shurraw S., Akbari A., Knoll G. A., Jaffey J., Clark H. D. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: A systematic review of the efficacy and safety data. Am J Kidney Dis 2006; 48: 8–20
   PubMed Web of Science ®Google Scholar
• Epstein M. Aldosterone blockade: An emerging strategy for abrogating progressive renal disease. Am J Med 2006; 119: 912–919
   PubMed Web of Science ®Google Scholar
• Dagenais G. R., Poque J., Fox K., Simoons M. L., Yusuf S. Angiotensin‐converting‐enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: A combined analysis of three trials. Lancet 2006; 368: 581–588
   PubMed Web of Science ®Google Scholar
• Mann J. F., Gerstein H. C., Poque J., Bosch J., Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 2001; 134: 629–636
   PubMed Web of Science ®Google Scholar
• Segura J., Campo C., Gil P., Roldan C., Vigil L., Rodicio J. L., et al. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 2004; 15: 1616–1622
   PubMed Web of Science ®Google Scholar
• Mancia G., Grassi G., Zanchetti A. New onset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3–10
   PubMed Web of Science ®Google Scholar
• Parving H. H., Lehnert H., Brochner‐Mortensen J., Gomis R., Andersen S., Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–878
   PubMed Web of Science ®Google Scholar
• Lewis E. J., Hunsicker L. G., Clarke W. R., Berl T., Pohl M. A., Lewis J. B., et al. Renoprotective effect of the angiotensin‐receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860
   PubMed Web of Science ®Google Scholar
• Barnett A. H., Bain S. C., Bouter P., Karlberg B., Madsbad S., Jervell J., , for the Diabetics Exposed to Telmisartan and Enalapril Study Group, et al. Angiotensin‐receptor blockade versus converting‐enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952–1961
   PubMed Web of Science ®Google Scholar
• Ruggenenti P., Fassi A., Ilieva A. P., Bruno S., Iliev I. P., Brusegan V., , for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941–1951
   PubMed Web of Science ®Google Scholar
• Haller H., Viberti G. C., Mimran A., Remuzzi G., Rabelink A. J., Ritz E., et al. Preventing microalbuminuria in patients with diabetes: Rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens 2006; 24: 403–408
   PubMed Web of Science ®Google Scholar
• Chatuverdi N., Sjoelie A. K., Svensson A., for the DIRECT Programme Study Group. The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design. J Renin Angiotensin Aldosterone Syst 2002; 3: 255–261
   PubMed Web of Science ®Google Scholar
• Grundy S. M., Cleeman J. I., Daniels S. R., Donato K. A., Eckel R. H., Franklin B. A., et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735–2752
   PubMed Web of Science ®Google Scholar
• Wilson P. W., D'Agostino R. B., Parise H., Sullivan L., Meigs J. B. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066–3072
   PubMed Web of Science ®Google Scholar
• Whaley‐Connell A., Sowers J. R. Chronic kidney disease and the cardiometabolic syndrome. J Clin Hypertens (Greenwich) 2006; 8: 546–548
   PubMedGoogle Scholar
• Chen J., Muntner P., Hamm L. L., Jones D. W., Batuman V., Fonseca V., et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004; 140: 167–174
   PubMed Web of Science ®Google Scholar
• Cordero A., Laclaustra M., Leon M., Grima A., Casanovas J. A., Luengo E., et al. Prehypertension is associated with insulin resistance state and not with an initial renal function impairment. A Metabolic Syndrome in Active Subjects in Spain (MESYAS) Registry substudy. Am J Hypertens 2006; 19: 189–196
   PubMed Web of Science ®Google Scholar
• American Diabetes Association, National Institute of Diabetes and Digestive and Kidney Diseases. Prevention or delay of type 2 diabetes. Diabetes Care 2004; 27 Suppl 1: S47–S54
   Google Scholar
• Haffner S. M. The prediabetic problem: Development of non‐insulin‐dependent diabetes mellitus and related abnormalities. J Diabetes Complications 1997; 11: 69–76
   PubMed Web of Science ®Google Scholar
• de Vegt F., Dekker J. M., Jager A., Hienkens E., Kostense P. J., Stehouwer C. D., et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA 2001; 285: 2109–2113
   PubMed Web of Science ®Google Scholar
• The DECODE Study Group: Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2‐hour diagnostic criteria. Arch Intern Med 2001; 161: 397–405
   PubMed Web of Science ®Google Scholar
• Saydah S. H., Loria C. M., Eberhardt M. S., Brancati F. L. Subclinical states of glucose intolerance and risk of death in the US. Diabetes Care 2001; 24: 447–453
   PubMed Web of Science ®Google Scholar
• Manley S. M., Meyer L. C., Neil H. A. W., Ross I. S., Turner R. C., Holman R. R. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. UKPDS 6. Diabetes Res 1990; 13: 1–11
   PubMedGoogle Scholar
• American Diabetes Association. Screening for type‐2 diabetes. Diabetes Care 2004; 27(Suppl 1): S11–S14
   Google Scholar
• Bakris G., Molitch M., Sowers J., Hewkin A., Fakouhi K., Bacher P. Differences in glucose tolerance between antihypertensive combination drugs in metabolic syndrome patients. Results of STAR. J Clin Hypertens (Greenwich) 2006; 8(suppl A): A177 [Abstract]
   Google Scholar
• Gaede P., Vedel P., Larsen N., Jensen G. V., Parving H. H., Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383–393
   PubMed Web of Science ®Google Scholar
• King H., Aubert R. E., Herman W. H. Global burden of diabetes, 1995–2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414–1431
   PubMed Web of Science ®Google Scholar
• Lewington S., Clarke R., Qizilbash N., Peto R., Collins R., for the Prospective Studies Collaboration. Age‐specific relevance of usual blood pressure to vascular mortality: A meta‐analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913
   PubMed Web of Science ®Google Scholar
• Tozawa M., Iseki K., Iseki C., Kinjo K., Ikemiya Y., Takishita S. Blood pressure predicts risk of developing end‐stage renal disease in men and women. Hypertension 2003; 41: 1341–1345
   PubMed Web of Science ®Google Scholar
• Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood‐pressure‐lowering regimens on major cardiovascular events: Results of prospectively‐designed overviews of randomised trials. Lancet 2003; 362: 1527–1535
   PubMed Web of Science ®Google Scholar
• Turnbull F., Neal B., Algert C., Chalmers J., Chapman N., Cutler J., , for the Blood Pressure Lowering Treatment Trialists' Collaboration, et al. Effects of different blood pressure‐lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410–1419
   PubMed Web of Science ®Google Scholar
• Casas J. P., Chua W., Loukogeorgakis S., Vallance P., Smeeth L., Hingorani A. D., et al. Effect of inhibitors of the renin–angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta‐analysis. Lancet 2005; 366: 2026–2033
   PubMed Web of Science ®Google Scholar
• The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, prediabetes, and cardiovascular disease: Executive summary. Eur Heart J 2007; 28: 88–136
   PubMed Web of Science ®Google Scholar